Context: Several studies found association between vitamin D levels and hypertension, coronary artery calcification, and heart disease.
Materials and Methods
The report of this protocol-driven systematic review adheres to the Quality of Reporting of Meta-analyses (QUOROM) standards for reporting systematic reviews of randomized clinical trials and reporting Meta-analyses of Observational Studies in Epidemiology (MOOSE) (15, 16) and was approved by the Vitamin D Task Force of The Endocrine Society. The quality of evidence was rated using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) methods (17) .
Eligibility criteria
Eligible studies were randomized trials that enrolled adults who received vitamin D supplementation and a concurrent comparison group that did not receive this intervention. We excluded studies in which the intervention was calcitriol or one of its analogs. We were interested in studies measuring the impact of the intervention on patient-important outcomes such as death, stroke, myocardial infarction (MI), and peripheral vascular disease. Secondarily, we were interested in the effect of vitamin D on cardiovascular risk factors (blood pressure, glucose, and lipids). Studies were included regardless of their language, size, or duration of patient follow-up. Ineligible references were nonrandomized studies, review articles, commentaries, and letters that did not contain original data. We also excluded the studies that reported a correlation of vitamin D levels with outcomes, but in which participants did not receive an intervention to raise their vitamin D levels, making causal inferences very weak.
Study identification
An expert reference librarian (P.J.E.) designed and conducted the electronic search strategy with input from study investigators with expertise in conducting systematic reviews. To identify eligible studies, we searched the electronic databases MEDLINE, EMBASE, Web of Science, SCOPUS, PEDRro (Physiotherapy Evidence Database); and regional medical databases (KoreanMed, Scielo, LILACs, Imbiomed, Index for Australian medical literature, Eastern Mediterranean Index, IndMed, ExtraMed) through August 2010. Search terms included vitamin D (as supplement, blood level, deficiency), vitamin D deficiency, individual metabolites of vitamin D, vitamin D2, vitamin D3 (explode cholecalciferols, ergocalciferols, adjusted for database-specific vocabulary), explode sunlight, hypoglycemia, hyperglycemia, blood glucose, exp diabetes mellitus; exp cardiovascular diseases, exp hypertension, ex cerebrovascular disorders/(including stroke), explode hyperlipidemia, exp lipids/bl; explode thromboembolism or explode thrombosis or cardiovascular risk (EMBASE), risk$ or mortality or incidence or prevalence or outcome, populations, specific study types such as crossover, observational studies. In addition, we reviewed the reference sections of eligible studies and available reviews and requested potentially eligible studies from content experts.
Data collection
Teams of reviewers working independently and in duplicate used web-based standardized forms and screened all abstracts and titles and, upon retrieval of candidate studies, reviewed the full text publications and determined study eligibility. Disagreements were resolved by consensus. Reviewers extracted descriptive, methodological, and outcome data from all eligible studies.
Data collected from studies included a description of the population (e.g. age, sex, dwelling, comorbidities, and vitamin D status), the intervention (the type of vitamin D raising intervention, dose, and route), study design and quality components, and data corresponding to the outcomes of interest (obtained at the end of treatment and before initiation of follow-up). We classified studies as including patients with vitamin D deficiency (probable, improbable, uncertain) based on: 1) author description; 2) reported serum 25-hydroxyvitamin D level (levels considered deficient were Ͻ20 ng/ml); or 3) enrollment of patients with at least two vitamin D deficiency risk factors including: elderly age, dark skin, living in a nursing home, living far from the equator, winter season, sunscreen use, wearing a veil, smoking, obesity, malabsorption disease, renal or liver disease, and use of medication such as anticonvulsants, glucocorticoids, antirejection and HIV medications (18) . For dichotomous outcomes, a 2ϫ2 table was created from each study, and if not available, the most adjusted summary measure and confidence interval (CI) values were used. For continuous outcomes, we collected from each study arm the number of participants, mean and SD, or the mean difference. The methodological quality of the trials was evaluated by pairs of blinded reviewers focusing on allocation concealment, blinding, funding, and loss to follow-up.
Statistical analysis
We performed random-effect meta-analysis (19) to pool relative risk (RR) and 95% CI across included studies. RR values under 1.00 are associated with decreased risk for a particular outcome as a result of a vitamin D-raising intervention. For continuous outcomes, we pooled the weighted mean difference across studies. The I 2 statistic, which estimates the percentage of total variation across studies that is due to heterogeneity rather than chance, was used to assess inconsistency (20) . I 2 values of 25% or less, 50%, and at least 75% represent low, moderate, and high inconsistency, respectively. Treatment effect-subgroup interactions were assessed by the ANOVA method and metaregression analysis. Statistical analysis was conducted using Comprehensive Meta-Analysis, version 2 (Biostat Inc., Englewood, NJ).
Subgroup and sensitivity analyses
To explore the causes of inconsistency and subgroup-treatment interactions, we defined a priori subgroups based on patient characteristics (patients with or without vitamin D deficiency; patients with or without comorbid conditions including prior cardiovascular events; males vs. females); extent of use of preventive interventions (aspirin, statins, and antihypertensives); duration of intervention (short-term vs. long-term); ad-herence to the intervention; control interventions (placebo or no intervention vs. calcium supplementation); whether the intervention raised the level of 25-hydroxyvitamin D3 or not; study design (appropriate allocation concealment vs. not); follow-up duration (Ն12 months vs. Ͻ12 months); number of patients lost to follow-up (Ն10% vs. Ͻ10%); and source of study funding (for profit or not for profit).
We conducted sensitivity analyses to determine whether review conclusions were affected by the choice of statistical methods (random-effects model vs. fixed-effect model) or when borderline eligible articles are included or excluded as well as the effect of excluding observational and cluster randomized studies.
Results
The initial search of the literature yielded 5584 citations, of which 51 eligible studies were selected with a good inter-reviewer agreement ( ϭ 0.80) (Supplemental Fig. 1 , published on The Endocrine Society's Journals Online web site at http://jcem.endojournals.org). Contact of all authors was attempted to verify data collected from their publication as well as to request additional or missing information. If an author did not respond to our initial request, a second request was attempted. We successfully contacted around 75% of the primary or secondary authors. Table 1 summarizes the characteristics of the included studies. Most studies recruited elderly women and coadministered calcium with vitamin D, and none used sun exposure or interventions other than vitamin D supplementation. Most studies effectively concealed the random allocation and blinded caregivers and patients. The methodological quality of included studies is summarized in Supplemental Table 1 .
Meta-analyses

Mortality
Most of the included studies reported on mortality (n ϭ 30). Pooling across studies showed a nonsignificant and potentially trivial reduction in mortality that was consistent across studies (RR, 0.96; 95% CI, 0.93, 1.00; P ϭ 0.08; I 2 ϭ 0%) (Fig. 1) .
MI, stroke, and peripheral vascular disease
Six studies reported the outcome of MI, and six reported on stroke. Meta-analyses showed no significant effect of vitamin D on MI (RR, 1.02; 95% CI, 0.93, 1.13; P ϭ 0.64; I 2 ϭ 0%) or stroke (RR, 1.05; 95% CI, 0.88, 1.25; P ϭ 0.59; I 2 ϭ 15%) (Fig. 1) . Five studies reported the outcome of peripheral vascular disease but with no events in either study arm.
Serum lipids, blood pressure, and blood glucose Table 2 shows pooled data for the effect of vitamin D on blood lipids, blood glucose, and blood pressure measurements. Vitamin D did not significantly affect any of the cardiovascular risk factors. However, the direction of vitamin D effect was consistent with reduction of all parameters measured except an increase in high-density lipoprotein cholesterol. Results were inconsistent across studies, and the pooled estimates were trivial in absolute terms.
Subgroup and sensitivity analyses
The planned subgroup analyses did not show any significant subgroup-effect interactions (Table 3) . This also includes the subgroup of studies reporting on vitamin D supplementation in vitamin D-deficient patients, in which we found no significant decrease in mortality, MI, or stroke (P Ͼ 0.05 for all outcomes).
The use of a fixed-effect model instead of a randomeffects model did not change study conclusions about any outcome. Excluding a study reporting death of a patient irrelevant to the intervention (21) 
Discussion
We conducted a systematic review and meta-analysis to summarize the best available research evidence regarding the effect of vitamin D on patient-important cardiovascular events and other cardiovascular risk factors. Previous systematic reviews of observational studies found significant associations between low vitamin D levels and the risk of cardiovascular disease (of variable definitions across the studies) and overall mortality (13, 14) . Our analysis of randomized trials in which vitamin D was given as an intervention, as opposed to a blood level, did not demonstrate a significant effect on death, stroke, MI, lipid fractions (except a trivial increase in high-density lipoprotein), blood pressure, and blood glucose values. Our estimate for the mortality outcome, although nonsignificant, is in the same direction (i.e. reduction in risk) of that reported in another systematic review by Grandi et al. (13) . The limitations of this review stem from the fact that many of the included studies were not designed to evaluate cardiovascular outcomes; therefore, if the ascertainment of these endpoints was systematically different between the intervention and the control groups, which might have occurred in the 18% of the studies that were unblinded, results could be biased. Publication and reporting biases cannot be ruled out in any systematic review, although we attempted to contact study authors to reduce the effect of these biases. Lastly, the heterogeneity in some of the analyses makes the overall evidence to be of low to moderate quality. There remains the possibility that potential cardiovascular benefit of vitamin D remains undetected due to confounding baseline cardiac risk factors that randomization failed to correct or due to the coadministration of calcium that may have a detrimental cardiovascular effect (26) . It is also important to note that randomized trials are likely to enroll participants without severe vitamin D deficiency who are less likely to benefit from vitamin D, which would drive the results toward the null. The strengths of this review relate to the comprehensive literature search and the bias protection measures undertaken during the conduct of the systematic review (i.e. selecting studies and evaluating outcomes and quality by blinded independent pairs of reviewers).
The effect of vitamin D on all-cause mortality remains unclear. Our analysis did not find an association, whereas a previous meta-analysis (27) found that vitamin D was associated with decreased all-cause mortality (RR, 0.93; 95% CI, 0.87-0.99). Our meta-analysis includes more trials (51 vs. 18) . Nevertheless, it is obvious that the choice of which trials to include in the meta-analysis is affecting the inference; hence, inference regarding mortality is not robust to the inclusion of evidence. It is plausible that vitamin D affects certain disease-specific mortalities such as cancer mortality (28, 29) , for example; and when data are aggregated, the noise-to-signal ratio hides such effect. It is also plausible that the current data, when restricted to studies with adequate protection of bias, sufficient follow-up, and documented increase in vitamin D level, become underpowered to detect benefits in cardiovascular outcomes. The answer to the mortality question will likely require a very large trial with long follow-up in which disease-specific mortality is measured and ascertained as a primary endpoint. Trials with factorial design similar to the Randomized Evaluation of Calcium or Vitamin D (RECORD) trial (30) in which patients can be randomized to differing doses of vitamin D with and without calcium will be needed to determine the optimal dose and the nonskeletal effects of these interventions.
The practice implications of this systematic review indicate that recommending vitamin D to patients to reduce cardiovascular risk is not consistent with the current evidence. Individuals will require the age-and sex-appropriate daily intake of vitamin D and may require additional supplementation for other indications such as bone health, but not for cardiovascular risk reduction. The accompanying guideline document developed by the task force of the Endocrine Society will provide additional practical advice and detailed recommendations regarding vitamin D supplementation (75) .
Conclusion
Trial data available to date are unable to demonstrate a statistically significant reduction in mortality and cardiovascular risk associated with vitamin D. The quality of the available evidence is low to moderate at best.
